Key Insights

Highlights

Success Rate

76% trial completion

Published Results

54 trials with published results (21%)

Research Maturity

106 completed trials (42% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

13.0%

33 terminated out of 253 trials

Success Rate

76.3%

-10.2% vs benchmark

Late-Stage Pipeline

4%

9 trials in Phase 3/4

Results Transparency

51%

54 of 106 completed with results

Key Signals

54 with results76% success33 terminated

Data Visualizations

Phase Distribution

189Total
Not Applicable (49)
Early P 1 (5)
P 1 (52)
P 2 (74)
P 3 (7)
P 4 (2)

Trial Status

Completed106
Unknown42
Terminated33
Recruiting30
Active Not Recruiting15
Not Yet Recruiting12

Trial Success Rate

76.3%

Benchmark: 86.5%

Based on 106 completed trials

Clinical Trials (253)

Showing 20 of 20 trials
NCT02133196Phase 2Recruiting

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

NCT05681039Phase 2RecruitingPrimary

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

NCT03952585Phase 2Active Not Recruiting

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

NCT07029152Not ApplicableRecruiting

Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis

NCT07209189Phase 2Recruiting

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

NCT03476330Phase 2Completed

Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia

NCT06731933Phase 2RecruitingPrimary

Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin

NCT07223424Phase 2Recruiting

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

NCT07361133Phase 2Not Yet RecruitingPrimary

Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer

NCT02128906Phase 2RecruitingPrimary

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

NCT05910827Phase 1Recruiting

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

NCT06753136Not ApplicableRecruiting

Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype

NCT02819752Phase 1Terminated

PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

NCT05070403Phase 2RecruitingPrimary

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

NCT06137274Phase 2RecruitingPrimary

Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC

NCT05027633Phase 2RecruitingPrimary

Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

NCT07241585Not ApplicableNot Yet Recruiting

Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)

NCT06996249Recruiting

Prospective Data Collection Initiative on Thoracic Malignancies

NCT06047379Phase 1Recruiting

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

NCT03786237Phase 1Completed

Rigosertib for RDEB-SCC

Scroll to load more

Research Network

Activity Timeline